Journal: Bioactive Materials

Article Title: Countering postoperative immune suppression with a self-assembling dendritic cell nanovaccine

doi: 10.1016/j.bioactmat.2026.05.005

Figure Lengend Snippet: In vivo therapeutic efficacy of advanced BAITs in a postoperative tumor model. (A) Schematic of in vivo experimental design. LLC tumors were surgically resected, and mice were re-challenged with LLC cells. Mice then received BAIT treatments. (B) Photographs of tumors and tumor weights at day 16 for each group (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗ is P < 0.001 by one-way ANOVA with Bonferroni post-hoc test). (C) Individual tumor growth curves over time (n = 5; ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (D) H&E-stained tumor sections. (E) TUNEL staining of tumor sections (brown, apoptotic cells). Black arrowheads mark TUNEL + areas. (F) Quantification of TUNEL + apoptotic cells (n = 5; ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (G) Representative immunofluorescence for Ki67 (green) in tumor tissues (nuclei in blue). The Apo-BAIT group shows greatly reduced Ki67 + proliferating cells. (H) Quantification of Ki67 + cell density (n = 5; ∗ is P < 0.05, ∗∗ is P < 0.01, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). Data are presented as mean ± SD.

Article Snippet: Anti-Ki67 mouse mAb (Cat# GB121141-100), anti-CD3 mouse mAb (Cat# GB15014-100), FITC-conjugated goat anti-mouse IgG (H + L) (Cat# GB22301), and Cy5-conjugated goat anti-mouse IgG (H + L) (Cat# GB27301) for immunofluorescence assays, and DAB (SA-HRP) TUNEL apoptosis detection kit were supplied by Servicebio (Wuhan, China).

Techniques: In Vivo, Drug discovery, Staining, TUNEL Assay, Immunofluorescence

Journal: IBRO Neuroscience Reports

Article Title: TNKS1 mediates the PTEN-PI3K/AKT pathway to regulate glycolysis and proliferation in gliomas

doi: 10.1016/j.ibneur.2026.01.007

Figure Lengend Snippet: Inhibition of TNKS1 expression can suppress cell proliferation in glioma xenografts.HE staining to observe cell morphology in each group (A); immunohistochemistry to detect Ki-67 values in cells from each group (B), with an asterisk (*) indicating a significant difference compared to the TNKS1-siRNA NC group, P < 0.05. Scale bar = 50 μm.

Article Snippet: The primary antibody used was rabbit anti-Ki67 antibody (HA721115, 1:200, HUABIO, USA), which was incubated overnight at 4°C.

Techniques: Inhibition, Expressing, Staining, Immunohistochemistry

Journal: Bioactive Materials

Article Title: Ameliorating post-infarction myocardial fibrosis and cardiac function via ROS-responsive hydrogel-mediated IL-11 antibody delivery

doi: 10.1016/j.bioactmat.2026.01.041

Figure Lengend Snippet: P-T@MAB injection promotes angiomyogenesis. Immunostaining images show TUNEL at 3 days post-injection (A), Ki67 (C), vWF (E), and CD31 (F) expression in heart sections at 4 weeks post-injection. Quantitative analysis of TUNEL (B), Ki67 (D), vWF (G), and CD31 (G) is presented (n = 5). Scale bars: 100 μm. n.s., not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: For immunostaining of biomarkers including Ki67 (CST, 9129), CD31 (Abcam, ab222783), vWF (Abcam, ab31630), α-SMA (Abcam, ab7817), Collagen I (CST, 66948), and Collagen III (Abcam, ab6310), samples were incubated overnight at 4 °C with primary antibodies diluted in blocking buffer.

Techniques: Injection, Immunostaining, TUNEL Assay, Expressing

Journal: Bone & Joint Research

Article Title: Naringin targets TGF-β1-mediated angiogenesis to enhance the osteogenic effect of induced membrane

doi: 10.1302/2046-3758.155.BJR-2025-0412.R1

Figure Lengend Snippet: Vascular formation and cell proliferation results of the induced membrane in rats. a) First-stage surgery of induced membrane technique (IMT). The white arrow refers to the bone defect, and the green arrow indicates the polymethylmethacrylate (PMMA) spacer. b) Second-stage surgery of IMT. The yellow arrow refers to the bone grafting area. c) Gross view, haematoxylin and eosin (H&E) and Masson staining results of the induced membrane. The yellow arrows indicate blood vessels. d) Immunohistostaining of platelet endothelial cell adhesion molecule-1 (CD31) in the induced membrane. The yellow arrows indicate CD31-positive vessels. e) Immunohistostaining of von Willebrand factor (vWF) in the induced membrane. The yellow arrows indicate vWF-positive vessels. f) Immunohistostaining of antigen Kiel 67 (Ki67) in the induced membrane. N = 6/group. Each value is presented as the mean (SD). *p < 0.05, **p < 0.01, ***p < 0.001 versus the Control group; #p < 0.05, ##p < 0.01, ###p < 0.001 versus the L-Naringin group.

Article Snippet: The slices were incubated with anti-platelet endothelial cell adhesion molecule-1 (CD31) antibody (1:50, Abcam, UK, ab281583), anti-von Willebrand factor (vWF) antibody (1:1,000, Servicebio, China, GB11020), anti-antigen Kiel 67 (Ki67) antibody (1:500, Servicebio, GB121141 ), anti-TGF-β1 antibody (1:500, Abcam, ab215715), anti-Phospho-SMAD2 antibody (p-SMAD2, 1:100, Abcam, ab188334), and anti-Phospho-SMAD3 antibody (p-SMAD3, 1:100, Bioss, China, bs-5616R).

Techniques: Membrane, Staining, Control

Journal: Cell Reports Medicine

Article Title: Spleen-targeted neoantigen mRNA vaccine induces ISG15 + CD8 + T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma

doi: 10.1016/j.xcrm.2026.102754

Figure Lengend Snippet: GZMA-F2R interaction mediates STNvac efficacy through T cell activation (A) Bubble plot showing ligand-receptor pairs between ISG15 + CD8 + T cells and APCs (B cells, CD4 + T cells, and DCs). (B) Violin plots showing F2R expression across T cell subsets and GZMA expression in APCs. (C and D) Therapeutic evaluation of STNvac co-administration with F2R antagonist (F2RA, SCH79797 ) ( n = 7 mice per group). (C) Bioluminescence images showing tumor burden in orthotopic HCC-bearing mice under the indicated treatments. (D) Survival curves of mice in different groups. (E and F) Multicolor immunofluorescence staining of intratumoral Ki67 + CD69 + ISG15 + CD8 + T cells. (E) Representative images. Scale bars, 20 μm. (F) Quantitative analysis of positive cell density in five randomly selected areas per tumor section. (G and H) Activation of human HCC TILs through the GZMA-F2R interaction. (G) Schematic illustration of the treatment schedule. (H) Quantitative analysis of 41BB + CD3 + CD8 + T cells after 24 h of GZMA stimulation ( n = 2 biological replicates, each analyzed in triplicate). Statistics: one-way ANOVA for (F) and (H); log rank (Mantel-Cox) test for (D). Mean ± SD. Significance levels: ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. See also and .

Article Snippet: Ki67 immunohistochemistry (Servicebio) and TUNEL assays (One Step TUNEL Apoptosis Assay Kit, Beyotime) were conducted to evaluate tumor cell proliferation and apoptosis.

Techniques: Activation Assay, Expressing, Multicolor Immunofluorescence Staining

Journal: bioRxiv

Article Title: Targeting THOC2-Mediated mRNA Export Induces PARP Inhibitor Vulnerability in DNA Repair-Competent Hepatocellular Carcinoma

doi: 10.64898/2026.05.17.725613

Figure Lengend Snippet: CCK8 A, colony formation (B, C) and EdU assays (D, E) were applied to evaluate the proliferation abilities of control or THOC2-knockdown Huh7 and MHCC97H cells (mean ± SEM; n = 3). Scale bar, 50 μm. ( F-J) Tumor xenograft model was constructed with stable control and THOC2-knockdown Huh7 cells (mean ± SEM; n = 6). Tumors were collected from sacrificed mice and tumor weights were measured ( G) . Tumor sizes were recorded consecutively to establish tumor growth curves ( H) . IHC staining of Ki67 in mouse subcutaneous tumors ( I-J) . Scale bar, 50 μm. ( K, L) Apoptosis experiment in the control and THOC2-knockdown cells after irradiation (IR) treatment (dose = 6 Gy). And histograms presented the percentage of apoptosis cells in each group (mean ± SEM; n = 3). ( M, N) IF assay shows γH2AX foci in the control and THOC2-knockdown cells after IR treatment (dose = 6 Gy). And histograms presented the average number of foci per cell in each group (mean ± SEM; n = 3). Scale bar, 20 μm. ( O, P) The alkaline comet assays show that the DSB repair capability is reduced in THOC2-knockdown Huh7 and MHCC97H cells. HCC cells are harvested at the indicated time (NT, and 0.5 h and 8 h post-treatment) upon IR treatment (6 Gy). The tail moment was analyzed using the CometScore software (mean ± SEM; n = 3). Scale bar, 200 μm. shCtrl: nontargeting shRNA; sh#2: sh-THOC2-2; sh#3: sh-THOC2-3; two-tailed unpaired Wilcoxon t test for ( A, C, E, L, N and P) ; two-tailed paired Wilcoxon t test for ( G, H and J) ; * P < 0.05; ** P < 0.01; *** P < 0.001 and **** P < 0.0001.

Article Snippet: Immunohistochemical staining of xenograft tumor tissues were performed by Wuhan Servicebio Technology with the following antibodies overnight: anti-ki67 (Servicebio, 1:600), anti-γH2AX (Merck, 1:200) and stained with goat anti-mouse IgG Ab (Servicebio, 1:200) at room temperature for 50 min and counterstained with hematoxylin.

Techniques: Control, Knockdown, Construct, Immunohistochemistry, Irradiation, Software, shRNA, Two Tailed Test

Journal: bioRxiv

Article Title: Targeting THOC2-Mediated mRNA Export Induces PARP Inhibitor Vulnerability in DNA Repair-Competent Hepatocellular Carcinoma

doi: 10.64898/2026.05.17.725613

Figure Lengend Snippet: The dose-response curves of PARP inhibitor Olaparib on Huh7 (A) , MHCC97H (B) and Hepa1-6 (C) cells, both control and THOC2 knockdown, were generated using CCK8 assays (mean ± SEM; n = 3). The half maximal inhibitory concentrations (IC50) were shown. ( D) Apoptosis experiment after THOC2 knockdown combined with PARPi (0.8 µM) in Huh7 and MHCC97H. PARPi: cells treated with Olaparib which is dissolved in DMSO; DMSO: cells treated with an equal volume of DMSO to Olaparib. (E, F) Immunofluorescence staining (IF) assay shows γH2AX foci in control and THOC2-knockdown MHCC97 cells treated with or without PARP inhibitor after ionizing radiation (IR; 0.6 Gy). And histograms presented the average number of foci per cell in each group (mean ± SEM; n = 3). Scale bar, 20 μm. ( G-I) Subcutaneous Hepa1-6 cells tumors, tumor growth curves and tumor weight in the indicated treatment groups (mean ± SEM; n = 6). The dose of Olaparib used is 50 mg/kg. ( J) Representative images of IHC Ki67 and γH2AX staining and the relative IHC scores (mean ± SEM; n = 6) in Hepa1-6 tumor tissues in ( G) . Scale bar, 50 μm. ( K) Representative images of TUNEL staining and the positive cells (%) (mean ± SEM; n = 6) in Hepa1-6 tumor tissues in e . Scale bar, 50 μm. The colors above the image represent the groups. shCtrl: nontargeting shRNA; sh#2: shTHOC2-2; sh#3: shTHOC2-3; sh#1: sh Thoc2 -1; PARPi: mouses treated with Olaparib (50 mg/kg); Control: mouses treated with an equal volume of DMSO to Olaparib; two-tailed unpaired Wilcoxon t test for ( D, F, I, J and K) ; two-way ANOVA for (H) ; ns, no significance; * P < 0.05; ** P < 0.01; *** P < 0.001 and **** P < 0.0001.

Article Snippet: Immunohistochemical staining of xenograft tumor tissues were performed by Wuhan Servicebio Technology with the following antibodies overnight: anti-ki67 (Servicebio, 1:600), anti-γH2AX (Merck, 1:200) and stained with goat anti-mouse IgG Ab (Servicebio, 1:200) at room temperature for 50 min and counterstained with hematoxylin.

Techniques: Control, Knockdown, Generated, Immunofluorescence, Staining, TUNEL Assay, shRNA, Two Tailed Test